Journal article
Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamole plus ASA with Clopidogrel) and Telmisartan versus Placebo in Patients with Strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS)
Abstract
BACKGROUND: Individuals with transient ischemic attack and ischemic stroke have a high risk of recurrent stroke and death. While acetylsalicylic acid (ASA, aspirin) is proven and accepted as standard therapy in these patients, recent trials demonstrate that a combination of ASA and dipyridamole (DP) or clopidogrel may be superior to ASA. Blocking the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin receptor …
Authors
Diener H-C; Sacco R; Yusuf S
Journal
Cerebrovascular Diseases, Vol. 23, No. 5-6, pp. 368–380
Publisher
Karger Publishers
Publication Date
2007
DOI
10.1159/000100105
ISSN
1015-9770
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAspirinBenzimidazolesBenzoatesClopidogrelDelayed-Action PreparationsDipyridamoleDouble-Blind MethodDrug CombinationsFemaleFibrinolytic AgentsHumansMaleMiddle AgedPlatelet Aggregation InhibitorsResearch DesignSecondary PreventionStrokeTelmisartanTiclopidineTreatment Outcome